Are postoperative prostate-specific antigen (PSA) levels of 0.08 ng/mL and 0.07 ng/mL after radical prostatectomy for prostate cancer concerning for recurrence?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

PSA Levels of 0.07-0.08 ng/mL After Radical Prostatectomy Do Not Meet the Standard Definition of Biochemical Recurrence and Should Be Monitored Closely

These PSA values are below the AUA-defined threshold for biochemical recurrence (≥0.2 ng/mL confirmed by a subsequent value ≥0.2 ng/mL), but they warrant close surveillance rather than immediate intervention. 1

Understanding the Biochemical Recurrence Definition

The American Urological Association established a standardized definition after reviewing 53 different definitions used across 145 studies. Biochemical recurrence after radical prostatectomy is defined as an initial PSA value ≥0.2 ng/mL followed by a subsequent confirmatory PSA value ≥0.2 ng/mL. 1 This threshold was selected as the most commonly used definition (appearing in 35 of the reviewed studies) and represents the optimal balance between sensitivity and specificity for predicting clinical disease progression. 2

Your PSA values of 0.08 and 0.07 ng/mL fall below this threshold and therefore do not constitute biochemical recurrence by current standards.

Clinical Significance of Low Detectable PSA

While these values don't meet recurrence criteria, they're not entirely reassuring either:

  • Patients with detectable PSA >0.2 ng/mL have a very high risk (64-93% at 1-3 years) of progression to higher PSA levels 3
  • However, the guideline specifically chose 0.2 ng/mL rather than lower thresholds (like 0.1 ng/mL) because lower cutpoints increase sensitivity but decrease specificity 2
  • A cutpoint of 0.4 ng/mL followed by another increase may better predict metastatic relapse risk, though 0.2 ng/mL remains the standard for defining recurrence 1

Recent research suggests that ultra-sensitive PSA measurements can identify patients at risk earlier, but this hasn't changed the standard definition. One 2026 study found that patients with PSA ≥0.03 ng/mL with subsequent increases had a 5-year recurrence-free survival of only 63.8%, particularly concerning in high-risk patients. 4 Another 2024 study showed that patients with PSA <0.02 ng/mL at 5 years post-surgery had a 98.5% 10-year recurrence-free survival. 5

Recommended Management Approach

For your situation with PSA values of 0.07-0.08 ng/mL:

  1. Confirm the trend with repeat PSA testing in 3 months 6

    • If PSA continues to rise and reaches ≥0.2 ng/mL with confirmation, this would meet biochemical recurrence criteria
    • If PSA remains stable or decreases, continue surveillance
  2. Consider your risk stratification factors 6:

    • Gleason Grade Group (higher grade = higher risk)
    • Pathologic stage (pT3 vs pT2)
    • Surgical margin status (positive vs negative)
    • PSA doubling time if trend continues (PSADT <6-12 months indicates higher metastatic risk) 1, 7
  3. Surveillance intervals 8, 6:

    • PSA every 3 months initially to establish trend
    • If stable, can extend to every 6 months
    • Digital rectal examination and imaging only if PSA rises to meet recurrence criteria

When to Consider Early Intervention

Do not initiate salvage therapy at these PSA levels. 6 However, if PSA rises to ≥0.2 ng/mL with confirmation:

  • Early salvage radiotherapy (at PSA <0.5 ng/mL) is associated with better outcomes than waiting for higher PSA levels 8, 6
  • The 2024 AUA/ASTRO/SUO guideline emphasizes not waiting for arbitrary PSA thresholds once the decision for salvage therapy is made 6
  • Consider PSMA-PET imaging if PSA reaches recurrence threshold to guide treatment planning 8, 6

Critical Pitfalls to Avoid

  • Don't treat based on ultra-sensitive PSA values alone without confirming a rising trend 6
  • Don't assume these low values represent benign residual tissue without serial monitoring - approximately 11% of post-prostatectomy patients develop PSA-only recurrence 9
  • Don't order extensive imaging (bone scan, CT) at these PSA levels - risk of detecting metastases is <3% even with PSA >30 ng/mL when PSADT >6 months 7

Your current PSA values require vigilant monitoring but not immediate treatment. Establish the trend over the next 3-6 months with serial PSA measurements.

References

Research

Risk assessment of late biochemical recurrence after radical prostatectomy: Usefulness of ultra-sensitive prostate-specific antigen measurement.

International journal of urology : official journal of the Japanese Urological Association, 2024

Research

[PSA and follow-up after treatment of prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008

Related Questions

What does a postoperative PSA of 0.06 ng/mL indicate after radical prostatectomy for prostate cancer?
After a detectable PSA ≥0.2 ng/mL following radical prostatectomy, how many weeks apart should a repeat PSA be performed to confirm biochemical recurrence of prostate cancer?
Can stem cells be used to treat advanced prostate cancer in a male patient with PSA >30 ng/mL, testicular pain, and retrograde ejaculation?
In a 67-year-old man with bilateral Gleason 3+4 prostate cancer who underwent radical prostatectomy, when should the first postoperative prostate-specific antigen (PSA) measurement be obtained?
In a 56-year-old man with Gleason 8 (4+4) prostate cancer status post radical prostatectomy, whose PSA has increased from 0.01 ng/mL to 0.03 ng/mL, what is the appropriate management?
What is the appropriate management for a patient with postoperative prostate-specific antigen (PSA) levels of 0.8 ng/mL and 0.7 ng/mL after radical prostatectomy for prostate cancer on [DATE]?
Should I administer an intravenous bolus of furosemide 20 mg now and reassess the patient in the morning?
Is ceftriaxone active against β‑lactamase‑producing Haemophilus influenzae?
In a patient with a recent renal transplant for end‑stage renal disease and a current estimated glomerular filtration rate of 84 mL/min/1.73 m², how should the chronic kidney disease stage be coded?
How does anemia precipitate decompensation of chronic heart failure?
How does albumin infusion precipitate volume overload in an older adult with chronic heart failure (reduced ejection fraction or diastolic dysfunction), hypoalbuminemia from liver disease or nephrotic syndrome, and impaired renal function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.